UNSPSC 51141503: Felbamate

This classification denotes an anticonvulsant agent with the molecular formula C11H14N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X72RBB02N8, chemically known as 1,3-propanediol, 2-phenyl-, dicarbamate but generally known as felbamate, which bears US NIH Compound Identifier 3331. European Medicines Agency schedules Felbamate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07526MIG.

UNSPSC 51141503 Felbamate is a Commodity code that maps to pharmaceutical products, though recent state and local opportunities tagged under this code do not actually focus on felbamate specifically—instead they cover a broader range of medications and medical products including naloxone, generic multi-source pharmaceuticals, over-the-counter products, and direct-to-manufacturer prescription programs. State and local buyers use this code family to source medications and pharmaceutical supplies for public health systems, county health departments, and cooperative purchasing consortia serving multiple jurisdictions. The work involves competitive bidding for pharmaceutical supply contracts, often with strict compliance requirements around FDA approval, Good Manufacturing Practices (cGMP), Drug Supply Chain Security Act (DSCSA) certification, insurance coverage thresholds, and wholesaler authorization. Issuing bodies range from county health departments to state health and human services commissions to multistate cooperative purchasing alliances; Seminole County, Florida and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) appear as active recent buyers.

Recent solicitations span Florida and Texas with multistate reach through cooperative vehicles. Seminole County, Florida released IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a July 26, 2023 response deadline. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, requesting vendor information on direct-to-manufacturer prescription capabilities for a Therapeutic Pharmacy Initiative. MMCAP, administered by the Minnesota Department of Administration and serving participating states including Oregon, posted RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 proposal deadline and July 1, 2026 contract start. All recent opportunities require detailed product compliance documentation, multiple insurance coverages, and adherence to federal pharmaceutical regulations, with performance penalties and administrative fees typically embedded in award structures.